BIT’s 9th Annual International Congress of Antibody-2017
About ICA-2017

The Annual International Congress of Antibodies (ICA), initiated from 2009, had been successfully organized in Beijing, Hangzhou Dalian and Nanjing, attracted more than 3,500 participants from 60 countries. ICA series congresses contribute to offering professionals in the field of antibody a multidisciplinary informative cooperative platform, and it has been the most definite and grand Antibody event in Asia. The ICA-2017, with the theme of ” New Darling of Immunotherapy” will be held during March 29-31, 2017 in Beijing, China.

Highlights of the ICA-2017
  • 500+ Attendees Coming from All over the World to Exchange Ideas, Build New Networks, and Foster Friendships
  • 200+ Oral Presentations Covering the Hot Topics and Cutting-edge Technology in the Field of Antibody
  • 80+ Exhibitors and 30+ Posters Showcasing the Emerging New Products and Technologies
  • Social Activities and Networking, Field Trip and Tech-tour, Build Partnerships, Find Huge Opportunities and Markets for Your Business over the World
  • Opportunities to Visit Beijing Natural and Cultural Landscape
Renowned Speakers of ICA-2017
Dr. Mitchell Ho, Senior Investigator, National Cancer Institute, NIH, USA Dr. Eric Risser, Senior Vice President, MacroGenics, Inc., USA Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc., Canada
Dr. Weikang Tao, Vice President and CEO of R&D Center, Jiangsu Henrui Medicine Co., Ltd., China Dr. Esther Una Cidon, Professor, Royal Bournemouth Hospital, UK Ms. Ningling Wang, Managing Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, China
Dr. Z. Ying Li, Partner, Steptoe & Johnson LLP, USA Dr. Weiping Shao, Director, Regeneron Pharmaceuticals, Inc., USA Dr. Paula Kim, President, TRAC-Translating Research Across Communities, USA
Dr. Lidia Anna Retkowska-Mika, Director, Office for Registration of Medicinal Products, Medical Devices and Biocides, Poland Dr. Ulrich Storz, Senior Partner, Michalski•Hüttermann & Partner, Germany Dr. George Lovrecz, Adjunct Professor, RMIT University, Australia
Ms. Xingmei Tan, Senior Engineer, Abcam(Hangzhou)Biotechnology Co. Ltd., China Dr. Mark I. Fitchmun, President and Senior Advisor, Somatek. Inc., USA Dr. Nirmesh Shah, Director, Apobiologix, USA
Dr. Matthew F. Heil, Chief Scientific Officer, Curemark LLC, USA Dr. Carole Schante, Principal Scientist, Novartis, Switzerland Dr. Marcus Mreyen, Director, Protagen Protein Services GmbH, Germany
Dr. Candida Fratazzi, President, BBCR Consulting, USA Dr. Sabrina Xu, Associate Director, Market Sales Development-Asia Emerging Biotech and Biosimilar markets, Merck Group, China Dr. Abhishek Saharia, Director, DiscoveRx Corporation, USA
Dr. Shawn Guse, President and CEO, Intuitive Biosciences, USA Dr. Hui Zhao, Principal Scientist, Agensys, USA Dr. Xianbin Yang, Director of R & D, AM Biotechnologies, USA
Dr. Steve Xiaofeng Yu, Director, Cyagen Biosciences, Inc, China Dr. David Franco, Head, GSK Vaccines, Belgium Dr. Martin Welschof, CEO, Opsona Therapeutics Ltd, Ireland
Dr. Matthias Germer, Senior Director, Biotest AG, Germany Dr. Patrick Liu, Vice President, Teva Pharmaceuticals Ltd., USA Dr. Kevin Heyries, Co-Founder, AbCellera, Canada
Dr. Heather Schwoebel, Manager, Harbour Antibodies, USA Dr. William L. Klein, Professor, University of California - Los Angeles, USA Mr. Rezan Güler, AlbaNova University Center, Sweden
Dr. Achim Treumann, director of NUPPA, University of Newcastle, United Kingdom Dr. Wei Wang, Senior Research Scientist, Vaccinex Inc, USA Dr. Agata Sobczynska-Malefora, Principal Clinical Scientist, St. Thomas' Hospital; Honorary Senior Lecturer, King's College London, UK
Dr. Noubar Kessimian, Vice-Chair, Department of Pathology & Laboratory Medicine, Brown University, School of Medicine, USA Dr. Xiaoying Zhang, Professor, Northwest A&F University, China Dr. Ludovic Duponchel, Professor, University of Lille, France
Dr. Ahuva Nissim, Reader, Queen Mary University of London, UK Dr. Matti A. Lang, Professor, The University of Queensland, Australia Dr. James M. Reuben, Professor, The University of Texas, USA
Dr. John Wright, Senior Investigator, National Cancer Institute, USA Dr. David Cayea, Chief Operating Officer, PlantForm Corporation, Canada Dr. Vera Hirsh, Associate Professor, McGill University Health Centre, Canada
Dr. Xiangdong Qu, General Manager, Hailu Biotechnology Limitted Company, China Dr. Alison MacKinnon, Principal Investigator, Queen’s Medical Research Institute, UK Dr. Jason Xiang, Vice President, Shanghai ChemPartner, China
Dr. Jonas Helma, Project Group Leader, Biozentrum der LMU, Germany Dr. Dimiter S. Dimitrov, Professor, National Cancer Institute, USA Dr. Weihong Wen, Associate Professor and Vice Director, Fourth Military Medical University, China
Dr. Alexis Rossignol, Project Manager, Clean Cells, France Dr. Jennifer Mataraza, Principal Investigator, Novartis, USA Dr. Senyon Choe, President, Mogam Biotechnology Institute, Korea
Dr. Andrea Nicolini, Professor, University of Pisa, Italy Dr. Jacqueline Whang-Peng, Director, Cancer Research Institute, Taipei Medical University Wan Fang Hospital, Taiwan Dr. Francesc Mitjans, Chief Scientific Officer, Lykera Biomed, USA
Dr. Qingcong Lin, Vice President, Shenogen Pharma, China Dr. Wenzhi Tian, Founder & CEO, ImmuneOnco Biopharma Co., Ltd, China Dr. Bernard Vanhove, Chief Operating Officer, OSE Immunotherapeutics, France
Dr. Abdel Halim, Vice President, Celldex Therapeutics, USA Dr. Zhong Wang, Professor, Sun Yat-Sen University, China Dr. Wei Xu, Senior Scientist, Hoffmann-La Roche, Switzerland
Dr. Liping Yu, Director, University of Colorado School of Medicine, USA Dr. Sundeep Kumar Upadhyaya, Senior Consultant, Indraprastha Apollo Hospitals, India Mr. Markus Sack, Research Scientist, RWTH Aachen University, Germany
Dr. Clifford Stocks, CEO, Theraclone Sciences, USA Dr. Edward Holson, Director, Broad Institute of MIT and Harvard, USA Dr. Charles J. Malemud, Professor, Case Western Reserve University, USA
Dr. Sylviane Pied, Professor, Institut Pasteur de lille, France Dr. Robert G. Gish, Principal, Robert G Gish Consultants LLC, USA Dr. Yvonne J. Rosenberg, CEO, PlantVax lnc., USA
Dr. Cath Mummery, Head of therapeutics BRU, University College London Hospitals, UK Dr. Olivier Léger, Independent Consultant, LEGER Consulting, entreprise individuelle, France Dr. Dennis Lin, Mycenax Biotech Inc., Taiwan
Dr. Rolf G. Werner, Professor, University of Tübingen, Germany Mr. Musaddeq Hussain, Principal Scientist, Merck Research Laboratories, USA Dr. Klaus Mauch, CEO, Insilico Biotechnology AG, Germany
Dr. Jong Wook Hong, Professor, Hanyang University, Korea Dr. Zhenlin Xu, Associate Professor, South China Agricultural University, China Dr. Roberto Crea, President and CEO, Protelica, Inc., USA
Dr. Xin Ge, Assistant Professor, University of California Riverside, USA Mr. Ruediger Mechsner, Principal Engineer, SAMSUNG Engineering, Korea Dr. Kerstin Otte, Professor, Biberach University of Applied Sciences, Germany
Dr. Vishal Agrawal, Scientist, Adimab, LLC, USA Dr. Boaz Tirosh, Assocaite Professor, The Hebrew University of Jerusalem, Israel    
Program Layout
Cluster 1: Main Conference
Part One: Opening Ceremony

Part Two: Keynote Forum

Cluster 2: Scientific Program  
Segment 1: Global Antibody Market Outlook, Policy and Business

Segment 2: Forefront in Antibody Research and Advanced Technologies

Segment 3: Hot Antibody Drug Targets

Segment 4: Next Generation Antibodies for Cancer Immunotherapy

Segment 5: New Antibody for Non-cancer Therapy

Segment 6: Antibody Engineering and Production
Cluster 3: Satellite Meeting  
Satellite Meeting 1: New Biologics Satellite Meeting 2: Biosimilars and Biobetters
Cluster 4: Workshop and Training Course

• Industrial Sponsored Symposia  
• Matchmaking and Biopartnering
• Round Table Discussion
• Training Course

Cluster 5: Posters and EXPO
ICA-2017 will provide an ideal platform to showcase your new technologies and products in China. It is developed to maximize exposure of exhibitors, with coffee breaks and poster sessions for delegates taking place in the exhibition area.
Why Reserve a Booth at ICA-2017
  • Exposure Your New Products, Technology, Innovations and Latest Development to Visitors
  • Explore Business Opportunities in China and Beyond
  • Interaction with Visitors Face-to-Face, Exchanging Conversation and Sharing Information
  • Spotlight Your Technology and Its Commercial Application Promote Business
  • Take Advantage of the Targeted Audience at the Conference and Network in the Hall
  • Highlight your Impact and Influence
  • Increased Visibility and Name Recognition
  • Access to Competitive Intelligence
Cluster 6: Sponsorship
ICA-2017 is one of the most effective international marketing platforms in the field of Antibody and related biotechnology, which offers a wide range of sponsoring categories for branding and highlighting your company in order to achieve the best publicity.
Expand Your Business - A Cost Effective Sponsorship
  • Get Cost and Time Effective Marketing Exposure and Boost Your Brand Recognition
  • Set Up Stronger Alliances, New Partnerships
  • Showcase Products and Services to a Targeted Prospects of Decision-makers
  • Opportunity to Speak and Announce Recent Company Development
  • Network from 800+ Professionals Offering Opportunities, before, during and after the Conference
Cluster 7: Social & Cultural Activities  
Activity 1: Welcome Banquet and Art Performance Activity 2: Industrial Sponsored Cocktail Party
Activity 3: Field Trip to Industry Park/Universities Activity 4: Beijing Impression Tech-Tour
Innova Biosciences
Rapid Novor Inc.
Guangzhou Furi Biological Technology CO., LTD
Mabplex International .Ltd

Desert King International

说明: C:\Users\zhangxinjian\Desktop\GBI.bmp

China Local Time
Days to Go!
Concurrent Congress

Operating Organizations
Official Travel Agency
Renewed Institute





Regeneron Pharmaceuticals, Inc

MorphoSys AG


The Scripps Research Institute


Institut Pasteur
Adimab, LLC, USA


Lonza Biologics plc

AbbVie Pharmaceuticals, Inc.



AM Biotechnologies, LLC

Merrimack Pharmaceuticals, Inc.

Mycenax Biotech Inc.


Johnson & Johnson Innovation

Merck Serono

MacroGenics, Inc.


Garrett & Dunner, LLP

Jones Day

Steptoe & Johnson LLP

King's College London

Brown University

Northwest A&F University

University of Colorado

BioProducts Laboratory Ltd,

Queen Mary University of London

China Pharmaceutical University

Intuitive Biosciences


AM Biotechnologies, LLC.

The First Affiliated Hospital of Zhengzhou University

VU University Medical Center

Lykera Biomed

Shenogen Pharma, China

ImmuneOnco Biopharma Co., Ltd, China

OSE Immunotherapeutics, France

University of Calgary, Canada
Case Western Reserve University, USA

Robert G Gish Consultants LLC, USA
University of Saskatchewan, Canada
University of Southern California, USA
University of Kentucky, USA
University College London Hospitals, UK

University of Science and Technology, China

Hanyang University, Korea
Vanderbilt University, USA
MSD Animal Health, UK

South China Agricultural University, China
Protelica, Inc., USA
University of California Riverside, USA
Sino Biological Inc., China
Protagen Protein Services GmbH, Germany
BBCR Consulting, USA

Xiamen University, China
University of Bologna, Italy
Pieris Pharmaceuticals, Inc., Germany

University of Washington

Sofia University

Masaryk University

University of Toronto

Imperial College

The Johns Hopkins University School of Medicine

University of Pittsburgh

University of Texas Southwestern Medical Center

Florida Atlantic University

Biotechrabbit GmbH

University of Southern California

Komtur Pharmaceuticals Group

Knobbe Martens Olson & Bear LLP

Johns Hopkins School of Medicine

Biberach University of Applied Sciences

University of Canterbury

University of Queensland

WuXi AppTec

University of Konstanz

Cyagen Biosciences

Lund University

Celldex Therapeutics

Sun Yat-Sen University

University of Lodz

University of Alabama at Birmingham

Apollo Gleneagles Hospitals

Pekin Union Medical College

Fountain Medical Development Ltd
BIT’s Upcoming Events
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2015-2016 BIT Congress Inc.